Leavell Investment Management’s Novo Nordisk NVO Stock Holding History

Leavell Investment Management’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-4,696	Closed	-$239K	–	612
2025 Q4	$239K	Sell	4,696 -1,469	-24%	-$75.1K	0.01%	547
2025 Q3	$342K	Sell	6,165 -85	-1%	-$4.97K	0.01%	483
2025 Q2	$431K	Buy	6,250 +978	+19%	+$66.5K	0.02%	431
2025 Q1	$371K	Buy	5,272 +1,304	+33%	+$108K	0.02%	434
2024 Q4	$341K	Buy	3,968 +475	+14%	+$51.4K	0.02%	446
2024 Q3	$416K	Buy	3,493 +8	+0.2%	+$1.07K	0.02%	415
2024 Q2	$497K	Buy	3,485 +1,662	+91%	+$220K	0.03%	357
2024 Q1	$236K	Buy	+1,823	New	+$217K	0.01%	454

Other funds holding NVO

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

DAM

Diamant Asset Management Ridgefield, Connecticut $147M AUM 25.76% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Leavell Investment Management's NVO Position: Q1 2026 in Review

Leavell Investment Management sold out of Novo Nordisk (NVO) in Q1 2026, closing a stake of 4,696 shares — an estimated $239K sold.

Leavell Investment Management first reported a position in NVO in Q1 2024 and held it in 8 quarters. The position peaked at $497K in Q2 2024. 1,277 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

Leavell Investment Management reported no remaining Novo Nordisk position as of Q1 2026 after selling out during the quarter.
Leavell Investment Management sold 4,696 Novo Nordisk shares in Q1 2026, an estimated $239K.
Leavell Investment Management first reported a position in Novo Nordisk in Q1 2024 and held it in 8 quarters.
Leavell Investment Management's Novo Nordisk position peaked at $497K in Q2 2024.
1,277 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Leavell Investment Management's 13F filing for Q1 2026, filed 12 May 2026.